Antengene (FRA:722) Repurchase of Stock: €0.00 Mil (TTM As of Dec. 2025)


FRA:722 Antengene Corp Ltd FRA:722
39 GF Score
Price €0.37
GF Value €0.16
! 5 Warning Signs
View Full Analysis

What is Antengene Repurchase of Stock?

Antengene FRA:722 +1.09% 39 Repurchase of Stock is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:722 with a GF Score™ of 39/100 and a GF Value™ of €0.16. The stock has 5 warning signs investors should review.

Antengene's Repurchase of Stock for the six months ended in Dec. 2025 was €0.00 Mil.

Antengene's Repurchase of Stock for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Antengene Repurchase of Stock Related Terms

Antengene Repurchase of Stock Historical Data

* Premium members only.

The historical data trend for Antengene's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antengene Repurchase of Stock Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Repurchase of Stock
Get a 7-Day Free Trial -6.66 -4.58 0.00 0.00 -0.17

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Repurchase of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:722
39GF Score
Antengene Corp Ltd FRA:722
Repurchase of Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antengene Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Repurchase of Stock →
What does a Repurchase of Stock of €0.00 Mil mean?
Antengene (FRA:722) has a Repurchase of Stock of €0.00 Mil as of Dec. 2025. Repurchase of Stock is the total amount of company share repurchases. View historical data for Antengene and its competitors.
Is Antengene's Repurchase of Stock too high?
Antengene's current Repurchase of Stock is €0.00 Mil. Overall, Antengene has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Antengene's Repurchase of Stock compare to VRTX and REGN?
Antengene's Repurchase of Stock of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Repurchase of Stock for a Biotechnology company?
A good Repurchase of Stock depends on the Biotechnology industry context. However, Repurchase of Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Repurchase of Stock mean?
A high Repurchase of Stock can signal that a stock is expensive relative to its fundamentals. Repurchase of Stock is the total amount of company share repurchases. View historical data for Antengene and its competitors. Antengene's current Repurchase of Stock is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antengene stock overvalued right now?
Antengene (FRA:722) has a current Repurchase of Stock of €0.00 Mil. The stock's GF Value™ is €0.16, compared to a current price of €0.37 — trading 132.5% above its estimated fair value. The current Repurchase of Stock is €0.00 Mil. Antengene's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Repurchase of Stock calculated?
Repurchase of Stock is calculated from a company's financial statements. For Antengene (FRA:722), the current Repurchase of Stock is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Antengene (FRA:722) Overvalued in 2026?

Based on GuruFocus' analysis, Antengene stock appears to be overvalued. The current stock price of €0.37 is trading 132.5% above its estimated GF Value™ of €0.16.

Key valuation signals for FRA:722:

  • Repurchase of Stock: €0.00 Mil
  • GF Value™: €0.16 vs. price of €0.37 (132.5% above fair value)
  • GF Score™: 39/100 with 5 warning signs

No single metric tells the full story. See the FRA:722 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Antengene Business Description

Other Exchanges 06996:Hong Kong
Address 1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically, it operates in the Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
39GF Score

Get the complete analysis for FRA:722

Repurchase of Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.37
Price
€0.16
GF Value